Hormone Receptor-positive Metastatic Breast Cancer

Also known as: Hormone Receptor Positive Metastatic Breast Cancer / Metastatic hormone receptor positive Breast cancer

Drug	Drug Name	Drug Description
DB12893	Sacituzumab govitecan	Sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.
DB00072	Trastuzumab	A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.

Drug	Drug Name	Target	Type
DB12893	Sacituzumab govitecan	Tumor-associated calcium signal transducer 2	target
DB12893	Sacituzumab govitecan	DNA topoisomerase 1	target
DB12893	Sacituzumab govitecan	Far upstream element-binding protein 1	target
DB12893	Sacituzumab govitecan	UDP-glucuronosyltransferase 1-1	enzyme
DB00072	Trastuzumab	Receptor tyrosine-protein kinase erbB-2	target

Drug	Drug Name	Phase	Status	Count
DB12001	Abemaciclib	4	Recruiting	1
DB00947	Fulvestrant	4	Recruiting	1